W hile violence against women has existed throughout human history, there is a growing recognition that this global crisis not only undermines the dignity, safety, and human rights of women but is also a major public health threat. Similarly, cardiovascular disease (CVD) has been recognized as one of the most important public health issues, accounting for one third of all deaths in women. 1 Growing evidence, including the work by Chandan et al 2 in the current issue of the Journal of the American Heart Association (JAHA) suggests that intimate partner violence (IPV) might increase the risk of CVD. While disparities that disfavor women persist with respect to CVD diagnosis, risk stratification, management, and outcomes, recognizing nontraditional CVD risk factors is an important opportunity to improve healthcare quality in women. Furthermore, the identification of IPV, a major global health threat affecting >30% of women, 3 as a risk factor for CVD has widespread implications with potential to impact healthcare delivery and public policy.
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IPV is defined as physical or sexual violence, emotional abuse, and stalking. In the United States, >30% of women have experienced contact physical or sexual IPV; 25% of women have experienced IPV severe enough that it resulted in injury, the need for medical care, or posttraumatic stress symptoms. 4 Approximately one third of men also experience IPV, although at a lower severity than women (ie, less often associated with injury/need for medical care). 5 Although IPV typically begins early in life, with its occurrence highest among adolescent and young-adult women, 6 it impacts women of all ages. Globally, IPV is the leading cause of homicide death for women. 7 IPV has a well-documented adverse impact on mental and physical health in women. Women who have experienced IPV are at increased risk of multiple mental health conditions (eg, depression, anxiety, eating disorders, posttraumatic stress disorder, and substance abuse) as well as physical health (eg, chronic pain, gastrointestinal problems, sexually transmitted infections, traumatic brain injury). 8, 9 IPV victimization is linked to CVD risk factors such as diabetes mellitus and hypertension in women 10, 11 and possibly also in men when severe and/or when he is also the perpetrator of violence. 12, 13 Furthermore, as demonstrated in the publication by Chandan et al, 2 IPV in women may also be associated with clinical CVD.
CVD is the leading cause of death in women worldwide. In the United States, CVD accounted for 299,578 deaths in women in 2017, about 1 in every 5 female deaths. 14 Although CVD mortality in women has declined over the past 30 years, this decline has recently plateaued, with an alarming increase in CVD mortality in women under age 55 years. 15 Furthermore, CVD is the second highest cause of disability-adjusted life years lost in women around the globe. 16 Significant healthcare disparities and gaps persist in the care and outcomes of women. Women are less likely to receive an early diagnosis of CVD than their male counterparts and less likely to receive appropriate, timely interventions. 1, 17 Women have worse outcomes than men after acute coronary syndromes such as higher mortality rates in younger women and higher postintervention complications. 18, 19 The cause of these sex and gender-related disparities in CVD includes delayed onset and atypical presentations of CVD in women, nontraditional gender-specific risk factors, unconscious gender bias, and underrepresentation of women in CVD trials. Approximately 56% of women do not know their CVD risk nor appreciate its significance. This lack of awareness is more profound among women in higher-risk groups, such as racial and ethnic minorities. 20 Furthermore, healthcare providers continue to utilize traditional approaches to assess and manage CVD in women, which may underestimate CVD risk and miss global factors (such as IPV), likely affecting their entire spectrum of care. Thus, CVD in women remains a global burden, underscoring the importance of a more comprehensive understanding of its cause and risk factors in women.
The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
The present investigation by Chandan et al tested the association of IPV (termed domestic abuse) with the risk of CVD. 2 They conducted a retrospective cohort study of women in a cohort of 18 547 women from a UK primary care registry. IPV and CVD information was extracted for these women from electronic medical records. Cases and controls were matched on variables including socioeconomic status, age, body mass index, and smoking. Participants were on average 37 years of age, with an average of 3 and 2.2 years of follow-up among the unexposed and in the IPV-exposed group, respectively. Despite matching, women who had a history of IPV more often had excessive drinking, type 2 diabetes mellitus, hypertension, lipid-lowering use, and comorbidities than women without a history of IPV. Furthermore, IPV was associated with a 31% increased risk for later CVD (with strongest effects for ischemic heart disease at 50% increased risk), a 51% increased risk for diabetes mellitus, and a 44% increased risk for total mortality.
Study strengths include its large sample size, matching, and medical-record-documented CVD outcomes. Weaknesses include its assessment of IPV, which was derived from medical records. The low rate of screening and detection of IPV in medical settings is well documented. 21 It is unclear whether the providers were required to screen for IPV or which coding system was implemented for IPV. It is likely, as the authors acknowledge, that only the most severe cases of physical IPV were detected here. Furthermore, IPV is not only physical: emotional IPV is common, severe, and in some studies, the form of IPV most related to disease risk. 22 Other limitations include the possible confounding effect of excessive alcohol drinking, more common in IPV-exposed women but not accounted for in analyses. Finally, the cohort was young and the follow-up time was limited for the detection of clinical CVD in women. Thus, the present study is based upon early or premature disease. Lastly, the study did not examine possible mechanistic explanations for the observed association.
The limitations of the study do not undermine its impact, but rather point to the importance of ongoing study of the impact of IPV on CVD risk in women. Important next steps include longitudinal cohort studies with rigorously assessed IPV via validated instruments. Follow-up into the ages in which women (seventh decade and beyond) typically develop clinical CVD is needed. Next steps should include investigation of the mechanisms underlying associations between IPV and CVD, which may include health and healthcare behaviors (eg, addictive behaviors, eating habits, sedentary behavior, disrupted sleep, adherence, and follow-up); psychological and economic factors linked to CVD risk (eg, psychological disorders, low socioeconomic attainment), 23 and direct biological mechanisms (eg, alterations in the hypothalamic-pituitary-adrenal axis, autonomic nervous system, chronic inflammation, epigenetic changes, and endothelial dysfunction). 24 The association of 2 highly pervasive conditions in women, IPV and CVD, highlight an important opportunity to tackle these major public health issues, which often begins in the healthcare setting. However, in a national survey on IPV and sexual violence, only 21% of women disclosed their victimization to a doctor or nurse. 25 US Preventive Services Task Force recommendations support routine screening of all women for IPV and point to standardized instruments to do so. 25, 26 In fact, there are several brief, well-validated screening tools for use in healthcare settings; optimal assessments address the multiple domains of IPV (physical, sexual, and emotional/psychological). The Table describes select screening tests recommended by the US Preventive Services Task Force, selected based on sensitivity, specificity, and facility of use in clinical settings. 4 Note that these scales have been validated for use in women, but their performance in men has not been established. Providers should be aware that IPV victims may not disclose their IPV immediately: a trusting relationship and multiple queries may be required before an individual discloses. Some research indicates a potential beneficial effect of screening alone for women experiencing IPV, yet full benefit is derived when screening is conducted in conjunction with intervention and ongoing follow-up. 27 Bestpractices for IPV screening and intervention include training staff and providers in effective interpersonal violence assessment, educating all patients in IPV regardless of disclosure, and clear protocols in the event of a disclosure (eg, proper documentation, treatment, referrals to psychological, community, and legal services, and ongoing follow-up). 28 Providers should be aware of local laws surrounding mandatory reporting of IPV and disclose the limits of confidentiality. An on-site multidisciplinary team approach to care that includes social services and behavioral health providers can help address the multiple sequelae of IPV.
Prevention of IPV is also paramount. Recent global efforts recognize the significant burden of gender-based violence. The United Nations adopted the 2030 Agenda for Sustainable Development, a list of goals that provide a framework for economic, social, and environmental development around the world. One key goal identifies violence against women as a key priority in achieving gender equality around the world. Gender violence is viewed as preventable and an essential component in global advancement. Similarly, the US State Department has identified gender violence as a key priority in its commitment to advancing gender equality around the globe and has developed strategic objectives to do so. These policy efforts represent a critical component of reducing violence against women.
The study by Chandan et al provides an important opportunity for the scientific community to shift its paradigm from traditional assumptions and models of CVD that place women at a disadvantage to a more comprehensive approach in order to reduce barriers and improve healthcare quality in women. As the impact of trauma and violence on chronic disease risk is increasingly documented, the time has come to consider a more expansive approach that considers the complex role of biological, social, and psychosocial stressors on the health and wellness of women. Only then can we improve existing public health policies and healthcare practices at a global level to improve the lives of millions of women around the world.
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